BlueStar Genomics gains breakthrough nod for pancreatic cancer test

Bluestar Genomics announced today that it received FDA breakthrough device designation for its pancreatic cancer test.

San Diego-based Bluestar’s proprietary noninvasive pancreatic cancer detection test is designed for use with patients with new-onset diabetes, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0